Nissui Pharmaceutical Co Ltd
TSE:4550
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nissui Pharmaceutical Co Ltd's latest stock split occurred on Nov 11, 2022
The company executed a 1-for-2460300 stock split, meaning that for every 2460300 shares held, investors received 1 new share.
The adjusted shares began trading on Nov 11, 2022. This was the only stock split in Nissui Pharmaceutical Co Ltd's history.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 24, 2026
|
|
Cue Biopharma Inc
NASDAQ:CUE
|
1-for-30
/30
|
0.5542 16.626 USD | 17.695 17.695 USD |
|
Apr 24, 2026
|
|
Medical Data Vision Co Ltd
TSE:3902
|
2-for-7253607
/3626803.5
|
1684 1684 JPY | N/A |
|
Apr 24, 2026
|
E
|
ESGL Holdings Ltd
NASDAQ:ESGL
|
1-for-3
/3
|
2.35 7.05 USD | 2.93 2.93 USD |
|
Apr 24, 2026
|
|
Metro Mining Ltd
ASX:MMI
|
1-for-20
/20
|
0.067 1.34 AUD | 1.3 1.3 AUD |
|
Apr 24, 2026
|
L
|
La Comer SAB de CV
OTC:LCMRF
|
115-for-114
x1.0087719298246
|
2.4715 2.4341 USD | 2.45 2.45 USD |
CUE
3902
MMI
Nissui Pharmaceutical Co Ltd
Glance View
Nissui Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of culture media and diagnostic reagents for medical institutions, research organizations, and food industries. The company is headquartered in Taito-Ku, Tokyo-To and currently employs 250 full-time employees. is a Japan-based company mainly engaged in the manufacture, purchase and sale of clinical diagnostic drugs, industrial diagnostic drugs, pharmaceuticals, among others. The firm operates through two business segments. The Diagnostic Drug segment is involved in the manufacture, purchase and sale of culture media, clinical diagnostic drugs, industrial diagnostic drugs and raw materials for medical institutions, research institutions and industrial facilities, as well as the purchase and sale of testing equipment and other equipment. The Pharmaceutical segment is involved in the manufacture, purchase and sale of pharmaceuticals and health foods for pharmacies and drugstores. The Company’s main products include clinical diagnostic drugs, industrial diagnostic drugs such as compactdry, pharmaceuticals such as therapeutics, nourishing tonics and health foods.
